The USPTO's Drug Patent and Exclusivity Study debunks false narratives and statistics against pharmaceutical patents, revealing that no studied innovative medicine had over 18 years of exclusivity.
The study indicates that the patent system has not been used to manipulate pricing through trivial variations, but rather to encourage genuine innovation in pharmaceuticals.
Data from the USPTO shows that the claims made by activists like I-MAK are misleading, which has led to misguided public policy decisions regarding pharma patents.
This report counters claims that patents restrict competition, instead demonstrating that they play a critical role in fostering innovation within the biopharmaceutical industry.
Collection
[
|
...
]